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Graft-versus-host disease (GVHD) is a major concern in transplantation patients.  Gut GVHD is accom-
panied by diarrhea,  abdominal pain,  and/or melena.  Although oral treatment with corticosteroids 
(CSs) is eﬀective in treating gut GVHD,  it can cause adverse reactions that aﬀect the entire body.  
Topical administration of CSs can be eﬀective in treating diseases in which lesions are limited locally,  
because adverse reactions can then be alleviated.  In this study,  we examine and discuss an enteric-
coated beclomethasone dipropionate (BDP) capsule (BDP-EC) formulated at Okayama University 
Hospital.  The BDP-EC did not dissolve in solution 1 (pH1. 2),  and began disintegrating in solution 2 
(pH6. 8) after 5min,  with a mean dissolution rate at 15min of 85ｵ.  We then used the capsule to treat 
a patient who developed gut GVHD after allogeneic hematopoietic stem cell transplantation.  Clinically,  
the frequency of diarrhea decreased after BDP-EC administration.  In addition,  we were able to 
decrease the prednisolone equivalent dose.  Symptoms associated with adverse reactions to BDP were 
not observed during the hospitalization period.  These ﬁndings suggest that the administration of 
BDP-EC in the early stages of gut GVHD may allow a reduction in the initial doses of systemic CSs.
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ematopoietic stem cell transplantation aims to 
recover hematopoiesis and immunity in patients 
with diseases in which hematopoietic function is dam-
aged,  such as leukemia,  lymphoma,  and myeloma [1].  
In allogeneic transplants,  hematopoietic stem cells 
from a human leukocyte antigen (HLA)-compatible 
donor are used.  The graft-versus-leukemia (GVL) 
eﬀect,  in which the hematopoietic cells of the donor 
attack the remaining tumor cells in the recipient,  has 
been well established.  As a result,  the trend is toward 
performing mini-transplantations that alleviate the 
heavy burden of pretreatment.  However,  graft-ver-
sus-host disease (GVHD),  an adverse immunological 
reaction in which T cells derived from the donor dam-
age the recipient cells,  is a common complication of 
allogeneic hematopoietic stem cell transplantation,  and 
a major concern.
　 A previous study showed that at the onset of acute 
GVHD,  81ｵ of patients had skin involvement,  54ｵ 
gastrointestinal involvement,  and 50ｵ liver involve-
ment after the ﬁrst allogeneic marrow transplant [1],  
which greatly aﬀected the success rate of transplanta-
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tions [2].  Gut GVHD,  which develops in the diges-
tive tract,  is accompanied by diarrhea,  abdominal 
pain,  and/or melena.  Corticosteroids (CSs) are used 
as the ﬁrst-line treatment for this disease.  However,  
while eﬀective anti-inﬂammatory agents,  CSs cause 
adverse reactions that aﬀect the whole body and are 
therefore considered unsafe [3].  Recently,  an enteric-
coated formulation of the antedrug beclomethasone 
dipropionate (BDP) was tested as an anti-inﬂamma-
tory treatment for gut GVHD [4,  5].  BDP is absorbed 
through the mucous membranes and is rapidly metabo-
lized and inactivated; it is considered to be an active 
glucocorticoid with strong anti-inﬂammatory activity 
and few adverse systemic eﬀects [6].
　 We prepared an enteric-coated BDP capsule 
(BDP-EC) at Okayama University Hospital (hereafter 
referred to as our institution) as an in-hospital formu-
lation,  and studied its pharmacologic properties.  We 
then used it to treat a patient who developed gut 
GVHD after an allogeneic hematopoietic stem cell 
transplant and examined the clinical usefulness of our 
BDP-EC formulation.
Methods
　 Preparation of BDP-EC. The BDP-EC cap-
sule was prepared using a method described in an 
article entitled “BDP-EC Capsules” in Byoin Yakkyoku 
Seizai (Japanese Society of Hospital Pharmacists ed. ) 
(Yakuji Nippo Ltd.,  Tokyo,  Japan) [7].  Japanese 
Pharmacopoeia gelatin No.  2 capsules (Matsuya Corp.,  
Osaka,  Japan) were ﬁlled with a mixture of 2mg of 
BDP and 0.198g of lactose.  Carboxymethyl ethyl 
cellulose (Freund Industrial Co.,  Ltd.,  Tokyo,  Japan) 
was used as the enteric-coating substrate.  Twenty 
layers of the enteric-coating liquid were airbrushed 
(Tamiya Inc.,  Shizuoka,  Japan; nozzle caliber,  0.3mm) 
onto each capsule body and cap.
　 Dissolution test. Sample enteric-coated cap-
sules were ﬁlled with Evans blue (Wako Pure 
Chemical Industries,  Ltd.,  Osaka,  Japan) as a marker,  
and used in a dissolution test.  The test was performed 
according to the 2nd (paddle) method of the Japanese 
Pharmacopoeia,  using 900mL (37.0 ± 0.5℃) of 2 test 
solutions: 1 (pH1.2) and 2 (pH6.8).  Paddle rotation 
was set at 50rpm.  Aliquots of the test solutions were 
collected over time and passed through a membrane 
ﬁlter (Nihon Millipore K.  K.,  Tokyo,  Japan; pore 
size,  0.45µm).  The absorbance of each ﬁltrate was 
measured at 600nm by ultraviolet absorptiometry to 
calculate the dissolution rates.
　 Clinical administration. The patient was a 
73-year-old man diagnosed with adult T-cell leukemia 
and admitted to the Division of Hepatology and 
Oncology at our institution for a cord blood trans-
plant.  After the transplant,  cyclosporine and myco-
phenolate mofetil were administered to prevent GVHD.  
However,  frequent watery diarrhea was observed 
from day 27 following transplantation,  and the patient 
was switched to the immunosuppressant tacrolimus 
hydrate.  In addition,  an intravenous drip infusion of 
prednisolone sodium succinate (PSL) was started on 
day 32 after the transplant.  Fourteen days after ini-
tiation of the PSL drip infusion,  daily oral adminis-
tration of 8mg of BDP-EC (2mg per dose,  4 times 
per day) was initiated and continued for 22 days [8].  
We examined medical records before and after BDP-EC 
administration and determined the following: frequency 
of diarrhea,  melena,  and abdominal pain as indices of 
clinical eﬃcacy; levels of C-reactive protein (CRP),  
serum potassium (K),  and hemoglobin (Hb) as labora-
tory values; and occurrence of adverse reactions due 
to CSs (infectability,  peptic ulcers,  blood pressure,  
adrenocortical insuﬃciency,  and psychoneurotic disor-
ders) throughout CS administration.
　 Ethical considerations. This study was 
reviewed and approved by the Institutional Review 
Board of our institution,  and informed consent was 
obtained from the patient.
Results
　 Dissolution behavior of the enteric-coated 
capsule. The results of the dissolution test are 
shown in Fig.  1.  The enteric-coated capsule did not 
dissolve in solution 1 (pH1.2) even after 120min,  and 
the dissolution rate for Evans blue was 0ｵ.  In solu-
tion 2 (pH6.8) the capsule did not disintegrate and the 
Evans blue did not dissolve for 5min; however,  the 
capsule began disintegrating after 5min,  and the mean 
dissolution rate at 15min was 85ｵ.
　 Therapeutic course and clinical administra-
tion. The drugs administered after the transplant 
and the frequency of diarrhea are shown in Fig.  2.  
Mild diarrhea was observed from day 23 following 
transplantation and increased after day 27 (frequency 
320 Acta Med.  Okayama　Vol.  67,  No.  5Murakawa et al.
321Enteric-coated Capsules of BeclomethasoneOctober 2013
0
20
40
60
80
100
0 30 60 90 120
time (minutes)
E
lu
tio
n 
ra
te
 (
%
) 
Solution 1
（pH1.2）
0
20
40
60
80
100
0 5 10 15 20 25 30
time (minutes)
Solution 2 
（pH6.8）
E
lu
tio
n 
ra
te
 (
%
) 
Fig. 1　 Dissolution rate of Evans blue in enteric-coated capsules determined by paddle rotation tests in vitro.  An enteric-coated Evans 
blue capsule was added to solution 1 (pH1.2) or solution 2 (pH6.8) for 30min.  Aliquots of the test solutions were collected over time and 
ﬁltered through a membrane ﬁlter.  The absorbance of each ﬁltrate was measured at 600nm by ultraviolet absorptiometry to calculate the 
dissolution rate.  Data represent the mean ± S. D.  for 6 experiments.
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Fig. 2　 Schedule of medication for adult T-cell leukemia after cord blood transplantation and the frequency of diarrheal episodes.  
Prednisolone (PSL) equivalent dose: Hydrocortisone (HC): PSL＝1 : 4; ST,  Sulfamethoxazole/trimethoprim (400mg: 80mg/tablet);  
BDP,  beclomethasone dipropionate.
of diarrhea: 20/day).  Abdominal pain and melena 
developed on day 29 and 31,  respectively.  A colonos-
copy revealed that the patient had gut GVHD with 
diﬀuse erosion mainly in the colon.  With this diagno-
sis (on day 32 after transplant),  a 14-day intravenous 
drip infusion of PSL (60mg/day) was begun.  Although 
the symptoms of abdominal pain and melena improved 
with PSL administration,  diarrhea persisted (day 44:  
frequency of diarrhea: 10/day).  As a result,  BDP-EC 
was started on day 45 following transplantation.
　 Fig.  2 shows the change in frequency of diarrhea 
when PSL and BDP-EC were administered.  The PSL 
dose was gradually decreased from 60 to 30mg/day 
(a 50ｵ decrease) during the 22 days that BDP-EC 
was administered.  At the end of the 22 days,  the 
patient was transferred to another hospital.  Despite 
the decrease in PSL,  there was no recurrence of 
abdominal pain or melena,  and no marked abnormali-
ties in any of the measured laboratory values,  includ-
ing CRP,  K,  and Hb levels (Fig.  3).  As may be seen 
in Fig.  3,  the patient had additional complications 
from the transplant and treatment: cytomegalovirus 
(CMV) infection was detected on day 24 after trans-
plantation,  a sleep disorder was observed early after 
transplant and lasted until the patient transferred 
hospitals,  and delirium was observed from day 62 
after transplantation.  No symptoms associated with 
the occurrence of peptic ulcers,  changes in blood 
pressure,  or adrenocortical insuﬃciency were observed 
during the hospitalization period.
Discussion
　 GVHD is one of the causes of early death after 
allogeneic hematopoietic stem cell transplantation,  and 
the use of methotrexate,  cyclosporine,  or CSs is 
recommended for hematopoietic stem cell transplanta-
tion [9].  PSL and other CSs possess strong anti-
inﬂammatory activities.  However,  since these drugs 
have systemic eﬀects,  they must be administered with 
care.  It is possible to separate the therapeutic activi-
ties from the adverse eﬀects of CSs by administering 
them topically.  Topical administration of CSs is an 
eﬀective way to treat diseases in which the lesions are 
limited locally because adverse reactions can be allevi-
ated.  In this study,  we prepared enteric-coated cap-
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Fig. 3　 Various symptoms and laboratory data after cord blood transplantation.  PSL,  prednisolone sodium succinate; Hb,  hemoglobin;  
K,  potassium; CRP,  C-reactive protein.
sules of BDP,  which has about 600 times more anti-
inﬂammatory activity than PSL and is believed to 
cause few systemic eﬀects due to its rapid metabolism 
by serum esterases.  We also clinically examined the 
usefulness of the administration of BDP-EC in a 
patient with gut GVHD.
　 BDP-EC was prepared using the method described 
in Byoin Yakkyoku Seizai (Yakuji Nippo Ltd.,  Tokyo,  
Japan) [7].  Our previous studies indicated that the 
disintegration of capsules begins at the joint of the cap 
and the body of the capsule.  We thus recognized that 
these vulnerable parts of the capsule required very 
careful coating.  The use of general or trigger-type 
spray bottles resulted in a wide diﬀusion of the liquid,  
making it very diﬃcult to spray a speciﬁc area.  In 
addition,  the amount of liquid sprayed varied,  and 
thus it was not possible to achieve a homogeneous 
coating of the capsules.  We chose instead an airbrush 
that allowed adjustments to the spray diﬀusion angle 
and the amount of enteric-coating liquid.  Despite these 
precautions,  it was diﬃcult to coat the capsules while 
adjusting the various conditions,  and diﬀerent opera-
tors may have introduced slight variations in the 
coating.
　 As it was critical for this formulation that the 
contents of the capsule be released only after reaching 
the small intestine,  we increased the number of coats 
from the generally accepted 5 to 20,  and focused 
particularly on spraying the joint of the capsules.  This 
was important because the procedure also increased 
the strength of the outer surface of the enteric-coated 
capsules.  In the dissolution tests,  the dissolution rate 
in solution 1 (pH1.2,  120min) was 0ｵ,  while that in 
solution 2 (pH6.8,  15min) was 85ｵ.  These results 
show that this is an eﬀective method for preparing 
enteric-coated capsules that release their contents in 
the small intestine (pH of about 6.8) rather than in the 
stomach (acidic conditions).
　 We then examined the clinical usefulness of oral 
administration of BDP-EC in a patient with gut 
GVHD.  The BDP-EC was started 23 days after the 
onset of diarrhea,  i.e.,  during the remission phase of 
gut GVHD.  The BDP-EC produced a marked reduc-
tion in the mean daily frequency of diarrhea,  while 
causing neither a relapse in abdominal pain or melena 
nor an increase in the frequency of diarrhea.  In addi-
tion,  initiation of BDP-EC allowed us to begin to 
gradually decrease the dose of PSL (i.e.,  the dose was 
reduced by 10mg per dose during the ﬁrst 7 days and 
by another 10mg per dose during the next 5 days).  
This schedule was very similar to the gradual 
decrease in CSs described in the published guidelines 
[9].  By the time the patient was transferred to another 
hospital,  the daily dose of PSL had been decreased by 
half.
　 In hematopoietic stem cell transplantation,  bone 
marrow function is completely lost due to the 
pretreatment; it is therefore very important to pre-
vent infections until neutrophil engraftment.  As PSL 
and other CSs have immunosuppressive activity,  
infectability should be considered.  There is,  more-
over,  a high expectation that the GVL eﬀect will 
occur in mini-transplantation therapy.  Because the 
immunosuppressive eﬀects of CSs can lead to a 
decrease in the GVL eﬀect,  it is preferable that CS 
use after transplant be of short duration.  In the cur-
rent study,  we were able to gradually decrease the 
dose of PSL with the administration of BDP-EC,  and 
also to avoid the long-term use of CSs.  We therefore 
argue that BDP-EC is useful in clinical applications.  
　 Avoiding the long-term use of CSs prevented 
CS-induced adverse reactions in this study.  We inves-
tigated clinical records to determine the onset of 
CS-induced adverse reactions during the systemic 
administration of CSs.  Our patient showed a positive 
CMV reaction on day 24 after transplantation.  CMV 
infection was conﬁrmed when the cumulative dose of 
CSs was 75mg (as converted to the weight of PSL).  
In addition,  since CS-induced CMV infection has been 
linked to the long-term administration of CSs,  we 
inferred that our patientʼs CMV infection was not 
induced by a decrease in the lymphocyte count,  but 
rather by lowered immunity due to transplantation and 
GVHD.  The risk of adrenocortical dysfunction has 
been known to increase with the long-term administra-
tion (about 6 months) of moderate or high doses of 
CSs.  In the present case,  considering the duration of 
CS administration (44 days),  it is unlikely that CSs 
played a role in adrenocortical dysfunction.
　 Our patient was observed to have a persistent sleep 
disorder from the time of the transplant,  as well as a 
psychoneurotic disorder in the form of delirium,  
observed from day 62 after transplantation.  Sleep 
disorder is a common adverse reaction associated with 
CSs.  Disease conditions and future treatment sched-
ules may also have aﬀected the patient psychologi-
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cally,  leading to the observed psychoneurotic disor-
ders.  However,  considering that 30mg or more of 
PSL was administered during the hospitalization 
period,  it is also possible that the CSs aﬀected the 
psychoneurological system.  The symptoms were well 
controlled by sleep-inducing and anti-anxiety drugs,  
and no extreme psychoneurotic disorders were observed.  
There were no marked changes in peptic ulcers or 
blood pressure even after the administration of CSs.  
The use of a proton-pump inhibitor was eﬀective in 
treating peptic ulcers.
　 We conclude from these results that the adminis-
tration of BDP-EC for gut GVHD makes it possible 
to gradually decrease the dose of concomitant systemic 
CSs early,  and that BDP-EC can help circumvent the 
long-term administration of CSs and prevent CS-induced 
serious adverse reactions.  Our ﬁndings thus suggest 
that BDP-EC is clinically useful.  Inﬂamed sites of gut 
GVHD often occur in the area spanning from the ileum 
to the cecum and in the ascending colon [5].  In the 
present case,  the main lesion was in the ileum; it is 
therefore possible that the contents of the prepared 
enteric-coated capsules reached the lesion.  However,  
various factors,  such as pH and duration of intestinal 
movement,  should be considered in future studies.  It 
will also be necessary to investigate coating substrates,  
additives,  and coating methods to improve site speci-
ﬁcity.
　 BDP-EC is currently administered concomitantly 
with systemic CSs in our institution.  This medication 
is highly valued by our physicians since it allows them 
to reduce doses of systemic CSs.  As the administra-
tion of BDP-EC in the early stage of gut GVHD may 
make it possible to reduce the initial dose of systemic 
CSs,  we plan to evaluate the early administration of 
BDP-EC for gut GVHD in future studies.
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